The year in charts

The year in charts

Tuesday, April 25, 2023 @ 7:00 am

Capital investments in Swiss biotech companies 2012-2022

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Total Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022 — Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed
their financial figures for 2022. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2013-2022

Number of employees in Swiss R&D biotech companies 2020-2022

Tags

You may also be interested in

Swiss Biotech Report 2026: Strong performance with new records in revenues and investments in privately funded companies

Total revenues reached a record CHF 7.5 billion in 2025 (CHF 7.2 billion in 2024) with more companies maturing to the commercial stage and a continuously growing demand for specialized CDMO services. Funding increased by 2.1% to CHF 2.6 billion. In a notable shift, investments in privately funded companies achieved a record CHF 1.15 billion – an increase of 38% compared to 2024, and a record 45%
May 5, 2026

Fraud campaigns without connection to the Swiss Biotech Association or the Swiss Biotech Day

We are tracking and escalating fraud campaigns targeting Swiss Biotech Association members and Swiss Biotech Day participants. Multiple fraudulent domains and Gmail accounts have already been identified and reported to their registrars and hosts; several have been taken down, but new ones continue to appear. Please read this alert carefully and share it within your organization.
April 16, 2026

Celonic partners with University Hospital Cologne on antibody manufacturing

The University Hospital Cologne (Universitätsklinikum Köln, UHC) has chosen the Celonic Group as its CDMO partner for advanced process development and GMP manufacturing of its monoclonal antibody targeting Pseudomonas aeruginosa, a Gram‑negative pathogen responsible for severe hospital‑acquired infections, biofilm‑driven persistence, and rising antimicrobial resistance. The antibody progra
August 12, 2026

PharmaBlock convenes industry leaders to advance green chemistry

As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for the PharmaBlock’s 3rd Green Chemistry Symposium (GCS) to explore how green chemistry and process innovation can accelerate the decarbonization of pharmaceutical manufacturing.
August 7, 2026

Pharvaris: Validation of clinical trial endpoints for treatment of angioedema attacks published

People with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social well-being Study results informed the design and endpoint selection of the ongoing Phase 3 CREAATE study
August 6, 2026

SOPHiA GENETICS: Collaboration to develop companion diagnostics for precision oncology therapies

SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
August 4, 2026